| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.06 | 0.08 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.056 | 0.08 |
| mRNA | NU-7441 | GDSC1000 | pan-cancer | AAC | -0.062 | 0.08 |
| mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | -0.059 | 0.08 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.064 | 0.08 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.08 |
| mRNA | NVP-ADW742 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.08 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.08 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.06 | 0.08 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.09 |